data_1qcm_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1qcm _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.471 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 12.6 p -168.58 47.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.303 -1.116 . . . . 0.0 109.319 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.471 ' HB2' ' O ' ' A' ' 2' ' ' SER . 34.8 m120 64.61 45.71 3.44 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.434 -0.791 . . . . 0.0 108.933 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.486 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 4.5 ttpt -66.46 -52.56 44.92 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.538 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -49.17 -24.47 4.82 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.405 ' N ' ' C ' ' A' ' 4' ' ' LYS . . . -78.22 -45.86 21.89 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.83 -0.806 . . . . 0.0 109.415 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.486 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 5.1 mt -57.85 -23.23 20.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.538 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 6.4 tt -58.32 -37.69 64.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.361 0.6 . . . . 0.0 109.744 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.418 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -77.83 -39.52 24.3 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.131 -1.588 . . . . 0.0 109.131 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.0 tp -47.85 -46.92 31.64 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.364 -1.08 . . . . 0.0 109.496 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 90.9 mtp . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.496 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -169.67 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.215 -1.167 . . . . 0.0 109.41 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.472 ' O ' ' HB1' ' A' ' 6' ' ' ALA . 55.1 m-20 -126.09 41.52 3.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.36 -0.837 . . . . 0.0 109.3 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.4 tttm -69.25 -51.6 35.91 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.514 -0.741 . . . . 0.0 109.255 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.54 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -50.14 -23.81 6.12 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 179.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.472 ' HB1' ' O ' ' A' ' 3' ' ' ASN . . . -73.45 -45.48 54.03 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.563 -0.963 . . . . 0.0 109.741 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.487 ' O ' ' HB3' ' A' ' 11' ' ' MET . 27.3 mm -59.29 -23.26 24.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 CA-C-O 121.903 0.859 . . . . 0.0 108.828 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.54 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 0.2 OUTLIER -57.64 -31.81 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.476 0.655 . . . . 0.0 109.93 -179.171 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.473 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -89.06 -38.42 6.82 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tp -99.89 72.28 1.7 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.448 -1.03 . . . . 0.0 109.619 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.487 ' HB3' ' O ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.591 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 t -171.62 58.95 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -1.126 . . . . 0.0 109.354 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -170.89 49.18 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.198 -0.939 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -61.93 -45.92 91.6 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.146 -0.971 . . . . 0.0 109.103 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.517 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -50.52 -23.32 6.29 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.77 -48.76 14.22 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.759 -0.848 . . . . 0.0 109.715 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.446 HD11 HG22 ' A' ' 7' ' ' ILE . 46.7 mm -55.11 -23.79 13.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 C-N-CA 119.591 -0.844 . . . . 0.0 108.737 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.517 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 2.8 tt -64.72 -37.82 81.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.475 -178.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.502 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -79.06 -49.67 6.24 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -43.34 -52.91 5.59 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.359 -1.083 . . . . 0.0 109.403 179.917 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 6.9 mmt . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.394 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.511 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 3.6 t 75.49 80.65 0.1 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.278 -1.131 . . . . 0.0 109.4 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.525 ' CB ' ' O ' ' A' ' 2' ' ' SER . 2.6 t-20 78.47 43.45 0.08 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.442 -0.786 . . . . 0.0 109.566 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.2 tttt -75.99 -50.97 13.39 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.334 -0.854 . . . . 0.0 109.002 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -53.61 -22.38 17.1 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.9 -42.67 60.34 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.83 -0.806 . . . . 0.0 109.245 179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.411 HG23 HD11 ' A' ' 7' ' ' ILE . 64.7 mt -58.69 -23.7 23.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.6 mm -64.57 -34.06 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.672 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.11 -47.29 74.2 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.576 -1.809 . . . . 0.0 108.576 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 22.7 tp -60.16 -38.69 83.92 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.669 -0.901 . . . . 0.0 109.54 179.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.452 ' HG3' ' O ' ' A' ' 11' ' ' MET . 9.6 tpt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.564 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.427 ' O ' ' HB3' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.427 ' HB3' ' O ' ' A' ' 1' ' ' GLY . 22.7 t 62.94 127.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.228 -1.16 . . . . 0.0 109.456 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -172.36 54.04 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.72 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.408 ' HA ' HD11 ' A' ' 7' ' ' ILE . 6.4 tttt -62.51 -44.84 95.38 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.083 -1.011 . . . . 0.0 109.13 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.477 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -51.06 -22.6 6.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.89 -49.26 8.02 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 121.772 -0.84 . . . . 0.0 109.376 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.408 HD11 ' HA ' ' A' ' 4' ' ' LYS . 41.7 mt -48.63 -27.23 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.877 0.846 . . . . 0.0 108.75 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.534 HG22 ' N ' ' A' ' 9' ' ' GLY . 1.9 tt -90.51 -43.16 14.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-O 121.411 0.624 . . . . 0.0 109.712 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.534 ' N ' HG22 ' A' ' 8' ' ' ILE . . . -57.79 -18.57 32.71 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.8 tp -69.87 -45.25 68.12 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.645 -0.915 . . . . 0.0 110.052 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.472 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 15.6 ptt? . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.068 -0.968 . . . . 0.0 109.59 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 21.4 m -63.61 105.41 0.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -1.163 . . . . 0.0 109.426 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.46 ' HB2' ' O ' ' A' ' 2' ' ' SER . 1.8 m-20 69.96 47.54 0.59 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.365 -0.835 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 ttpt -63.34 -50.96 67.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.35 -0.844 . . . . 0.0 108.73 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.517 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -51.48 -23.81 10.08 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 178.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.423 ' HB1' ' O ' ' A' ' 3' ' ' ASN . . . -76.0 -46.13 31.03 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.873 -0.781 . . . . 0.0 109.242 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 13.7 mm -55.37 -24.25 15.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.531 HG21 ' N ' ' A' ' 9' ' ' GLY . 7.2 tt -67.8 -36.27 75.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.323 -178.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.531 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -89.72 -22.11 37.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.419 ' O ' ' C ' ' A' ' 11' ' ' MET . 48.9 tp -73.32 -34.96 65.97 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.378 -1.071 . . . . 0.0 109.784 -179.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.419 ' C ' ' O ' ' A' ' 10' ' ' LEU . 11.3 ptm . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.413 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' A' ' 1' ' ' GLY . 1.4 t 75.53 141.65 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.291 -1.123 . . . . 0.0 109.424 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.409 ' OD1' ' HB1' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -156.85 51.36 0.49 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 179.909 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.414 ' C ' ' N ' ' A' ' 6' ' ' ALA . 15.8 tttm -64.38 -48.16 76.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.468 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -47.86 -25.52 3.68 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.414 ' N ' ' C ' ' A' ' 4' ' ' LYS . . . -82.11 -48.66 11.08 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.829 -0.807 . . . . 0.0 109.514 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 15.3 mm -50.43 -25.68 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 119.508 -0.877 . . . . 0.0 108.727 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.485 HG21 ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -72.17 -40.56 66.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.821 -0.55 . . . . 0.0 110.449 -179.207 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.485 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -72.92 -47.63 24.26 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 9' ' ' GLY . 19.0 tp -40.93 -44.35 2.3 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.463 -1.022 . . . . 0.0 109.486 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 34.1 mtt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.368 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.64 163.42 12.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.324 -1.104 . . . . 0.0 109.41 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.431 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 2.0 p-10 -139.32 46.82 1.91 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.468 ' HA ' HD11 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -67.9 -47.09 69.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 0.0 109.533 -179.738 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.443 ' O ' ' HB ' ' A' ' 8' ' ' ILE . . . -45.88 -27.32 2.3 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.431 ' HB2' ' O ' ' A' ' 3' ' ' ASN . . . -67.84 -53.55 25.9 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.847 -0.796 . . . . 0.0 109.419 179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.468 HD11 ' HA ' ' A' ' 4' ' ' LYS . 1.9 mp -50.23 -26.61 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.443 ' HB ' ' O ' ' A' ' 5' ' ' GLY . 36.5 mm -75.38 -40.39 42.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.333 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.12 -23.6 64.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.4 ' O ' ' OXT' ' A' ' 11' ' ' MET . 29.6 tp -65.36 -45.93 82.18 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.698 -0.884 . . . . 0.0 109.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.4 ' OXT' ' O ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.681 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.414 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.33 139.18 11.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.208 -1.172 . . . . 0.0 109.089 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.11 52.06 1.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.193 -0.942 . . . . 0.0 109.54 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -68.05 -42.76 80.05 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.515 -0.741 . . . . 0.0 109.305 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -50.16 -24.94 7.31 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' HG ' ' A' ' 10' ' ' LEU . . . -73.2 -45.09 58.36 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 122.017 -0.696 . . . . 0.0 109.637 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.484 HD11 HG22 ' A' ' 7' ' ' ILE . 15.9 mm -63.02 -22.27 30.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-O 122.18 0.991 . . . . 0.0 108.368 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -66.0 -11.07 12.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-O 121.455 0.645 . . . . 0.0 110.095 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -114.1 -36.43 1.36 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' A' ' 6' ' ' ALA . 31.5 mt -59.48 -35.52 74.26 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.511 -0.994 . . . . 0.0 108.517 179.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.421 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.578 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 22.6 m -84.65 174.2 10.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.567 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.46 ' CB ' ' O ' ' A' ' 2' ' ' SER . 3.8 m-80 72.76 54.84 0.14 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.333 -0.854 . . . . 0.0 109.539 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.48 -48.95 79.52 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.25 -0.906 . . . . 0.0 108.918 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.519 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -52.53 -24.23 16.74 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.095 -2.002 . . . . 0.0 108.095 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.447 ' HB1' ' HB3' ' A' ' 3' ' ' ASN . . . -73.32 -44.11 59.6 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 46.4 mt -54.82 -24.11 13.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.519 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 6.6 tt -58.15 -41.14 80.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 120.134 -0.626 . . . . 0.0 109.867 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' A' ' 8' ' ' ILE . . . -74.21 -44.1 29.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 40.6 tp -43.91 -37.21 2.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.435 -1.038 . . . . 0.0 109.317 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 11.6 mtm . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.543 179.941 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -118.71 165.97 13.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.241 -1.153 . . . . 0.0 109.639 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 12.0 p-10 -163.83 49.85 0.14 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.308 -0.87 . . . . 0.0 109.308 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 5' ' ' GLY . 10.3 ttmt -68.0 -49.95 58.48 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.338 -0.851 . . . . 0.0 109.522 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 4' ' ' LYS . . . -46.04 -28.03 2.76 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 7' ' ' ILE . . . -66.97 -54.25 23.76 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.865 -0.785 . . . . 0.0 109.076 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.493 HD11 HG22 ' A' ' 7' ' ' ILE . 42.3 mm -47.53 -26.92 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.486 ' O ' ' HG2' ' A' ' 11' ' ' MET . 11.4 mm -82.13 -39.04 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.021 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.14 -23.1 71.23 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.0 -50.37 72.31 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.587 -0.949 . . . . 0.0 109.545 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.486 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 3.0 ptt? . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.496 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -132.7 100.75 5.04 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.209 -1.171 . . . . 0.0 109.637 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -129.04 41.66 3.44 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' C ' ' N ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -68.9 -50.86 45.89 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.358 -0.839 . . . . 0.0 109.04 179.791 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.486 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -47.48 -25.67 3.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.322 -1.911 . . . . 0.0 108.322 179.263 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.406 ' N ' ' C ' ' A' ' 4' ' ' LYS . . . -75.04 -48.21 25.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.793 -0.827 . . . . 0.0 109.292 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 21.2 mm -53.6 -24.55 9.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.836 0.826 . . . . 0.0 108.809 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.538 HG21 ' N ' ' A' ' 9' ' ' GLY . 0.1 OUTLIER -68.96 -39.29 79.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 120.281 -0.567 . . . . 0.0 110.28 -178.944 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.538 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -75.23 -57.48 4.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.432 ' C ' ' O ' ' A' ' 9' ' ' GLY . 14.7 tp -44.64 -39.4 5.01 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.428 -1.042 . . . . 0.0 108.744 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 2.1 ttm . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.785 179.578 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.47 -170.77 1.91 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.289 -1.124 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.45 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 1.7 m120 -134.13 44.83 2.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.455 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 44.1 tttt -62.84 -44.19 96.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.394 -0.816 . . . . 0.0 109.069 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.491 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -52.51 -22.11 10.4 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 179.495 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.45 ' HB2' ' O ' ' A' ' 3' ' ' ASN . . . -75.94 -49.87 16.57 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.598 -0.943 . . . . 0.0 109.09 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 11.4 mt -51.34 -25.55 4.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.554 -0.858 . . . . 0.0 108.719 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.498 HG21 ' N ' ' A' ' 9' ' ' GLY . 0.3 OUTLIER -66.9 -41.63 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 119.792 -0.763 . . . . 0.0 109.971 -179.063 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.498 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -68.22 -41.95 84.79 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 9' ' ' GLY . 6.0 tp -41.65 -38.36 1.38 Allowed 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.507 -0.996 . . . . 0.0 109.241 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.666 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.424 ' C ' ' OD1' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -175.84 156.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.287 -1.126 . . . . 0.0 109.135 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.424 ' OD1' ' C ' ' A' ' 2' ' ' SER . 0.0 OUTLIER -134.13 45.02 2.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.126 -0.984 . . . . 0.0 109.467 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 tttt -64.99 -43.0 94.0 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.36 -0.838 . . . . 0.0 109.172 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.509 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -50.22 -27.64 11.57 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 179.127 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -68.53 -45.99 70.73 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.866 -0.785 . . . . 0.0 108.975 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 47.5 mm -51.11 -25.09 3.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.515 HG21 ' N ' ' A' ' 9' ' ' GLY . 0.3 OUTLIER -67.68 -41.0 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.669 -0.644 . . . . 0.0 110.269 -179.275 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.515 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -78.73 -64.59 1.94 Allowed Glycine 0 N--CA 1.488 2.1 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 179.569 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.472 ' O ' ' C ' ' A' ' 11' ' ' MET . 3.1 tp -45.68 -59.25 2.87 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.514 -0.992 . . . . 0.0 108.374 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.472 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.056 179.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 5.7 m -118.45 72.9 0.89 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.148 -1.207 . . . . 0.0 109.167 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.48 ' CB ' ' O ' ' A' ' 2' ' ' SER . 1.1 m-20 167.07 57.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.11 -0.994 . . . . 0.0 109.752 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.4 ttmt -61.63 -49.88 74.8 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.094 -1.004 . . . . 0.0 109.136 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -50.62 -24.19 7.43 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 108.585 -1.806 . . . . 0.0 108.585 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 3' ' ' ASN . . . -78.05 -41.68 34.73 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.719 -0.871 . . . . 0.0 109.468 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.522 ' O ' ' CB ' ' A' ' 11' ' ' MET . 13.0 mm -60.46 -21.16 22.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.763 0.792 . . . . 0.0 109.052 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 1.1 tt -76.68 -22.89 15.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.824 -0.548 . . . . 0.0 111.206 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.48 -41.92 3.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.3 mt -63.99 -42.67 97.12 Favored 'General case' 0 C--N 1.296 -1.742 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.522 ' CB ' ' O ' ' A' ' 7' ' ' ILE . 1.2 tpt . . . . . 0 C--N 1.302 -1.5 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.334 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.9 t -144.06 140.6 29.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -1.156 . . . . 0.0 109.42 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.403 ' OD1' ' N ' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -143.81 44.91 1.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.258 -0.901 . . . . 0.0 109.389 179.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.467 ' HA ' HD11 ' A' ' 7' ' ' ILE . 12.0 ttpt -62.91 -43.43 98.8 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.476 -0.765 . . . . 0.0 109.228 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.536 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -52.29 -20.89 7.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.7 -49.5 13.0 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.649 -0.912 . . . . 0.0 109.672 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.467 HD11 ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -58.92 -23.27 23.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.536 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -58.65 -33.71 49.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.294 0.569 . . . . 0.0 110.144 -178.826 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.462 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -62.87 -34.37 89.64 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 179.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.2 tp -54.07 -50.78 65.99 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.561 -0.964 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 18.0 mtm . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.053 -0.975 . . . . 0.0 109.477 179.853 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 17.6 m -119.55 154.3 34.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.299 -1.118 . . . . 0.0 109.63 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.46 ' CB ' ' O ' ' A' ' 2' ' ' SER . 3.8 m120 73.33 55.92 0.11 Allowed 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.299 -0.876 . . . . 0.0 108.935 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 ttpm? -60.98 -50.22 74.25 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.258 -0.901 . . . . 0.0 108.625 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.529 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -48.97 -25.89 5.49 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.476 ' O ' ' HG ' ' A' ' 10' ' ' LEU . . . -77.53 -45.72 24.55 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.976 -0.72 . . . . 0.0 109.569 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.475 ' O ' ' HB3' ' A' ' 11' ' ' MET . 41.9 mt -59.57 -20.85 19.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 CA-C-O 121.962 0.887 . . . . 0.0 108.884 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.529 ' CG2' ' O ' ' A' ' 5' ' ' GLY . 6.5 tt -58.73 -29.04 38.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.284 0.564 . . . . 0.0 110.265 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.21 -48.39 0.77 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.479 ' O ' ' O ' ' A' ' 11' ' ' MET . 61.4 mt -48.16 -41.02 25.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.216 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.479 ' O ' ' O ' ' A' ' 10' ' ' LEU . 3.9 ptm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.622 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -165.76 -174.22 2.99 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -1.152 . . . . 0.0 109.185 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.435 ' O ' ' HB1' ' A' ' 6' ' ' ALA . 0.2 OUTLIER -119.26 39.25 3.62 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.141 -0.975 . . . . 0.0 108.943 179.589 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.31 -44.6 96.12 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.513 ' O ' ' CG2' ' A' ' 8' ' ' ILE . . . -50.57 -23.56 6.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.284 -1.926 . . . . 0.0 108.284 179.045 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 3' ' ' ASN . . . -82.76 -47.28 12.13 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.789 -0.83 . . . . 0.0 109.521 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 7' ' ' ILE . 80.7 mt -55.15 -24.25 14.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.526 HG21 ' N ' ' A' ' 9' ' ' GLY . 8.4 tt -68.0 -36.05 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.917 -0.489 . . . . 0.0 110.595 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.526 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -67.21 -46.15 74.36 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 60.0 tp -42.83 -43.2 3.92 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.577 -0.955 . . . . 0.0 109.555 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.546 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.17 126.48 27.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.251 -1.146 . . . . 0.0 109.446 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 175.34 51.26 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.913 . . . . 0.0 109.603 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.483 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 16.4 tttt -62.21 -46.56 88.33 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.266 -0.896 . . . . 0.0 109.228 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.47 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -48.78 -24.69 4.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.281 -1.928 . . . . 0.0 108.281 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.408 ' N ' ' C ' ' A' ' 4' ' ' LYS . . . -78.26 -52.66 8.32 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.883 -0.775 . . . . 0.0 110.122 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.483 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 4.2 mt -52.93 -24.46 7.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 C-N-CA 119.339 -0.944 . . . . 0.0 108.562 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.529 HG21 ' N ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -71.86 -39.1 67.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.196 0.522 . . . . 0.0 110.168 -179.301 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.529 ' N ' HG21 ' A' ' 8' ' ' ILE . . . -76.63 -60.51 2.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' O ' ' A' ' 9' ' ' GLY . 25.9 tp -43.3 -52.13 5.93 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.104 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 29.8 tpp . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.051 -0.976 . . . . 0.0 109.3 179.791 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 p -67.12 125.05 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.307 -1.113 . . . . 0.0 109.438 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -167.52 53.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.197 -0.94 . . . . 0.0 109.346 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.9 tttm -67.83 -42.52 81.33 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.101 -0.999 . . . . 0.0 109.555 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.56 ' O ' HG21 ' A' ' 8' ' ' ILE . . . -57.53 -16.96 24.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.417 -1.873 . . . . 0.0 108.417 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -92.11 -42.41 9.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.671 -0.9 . . . . 0.0 108.991 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 20.5 mm -52.92 -25.66 9.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.793 0.806 . . . . 0.0 109.104 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.56 HG21 ' O ' ' A' ' 5' ' ' GLY . 1.1 tt -81.51 -42.79 19.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.82 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.476 ' N ' ' CG2' ' A' ' 8' ' ' ILE . . . -69.02 -18.74 73.09 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.3 tp -69.48 -45.15 69.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.472 -1.016 . . . . 0.0 109.192 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' MET . . . . . 0.43 ' SD ' ' HA ' ' A' ' 8' ' ' ILE . 1.5 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.411 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.459 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 12.6 p -168.58 47.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.303 -1.116 . . . . 0.0 109.319 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 34.8 m120 64.61 45.71 3.44 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.434 -0.791 . . . . 0.0 108.933 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.951 ' HA ' HD12 ' A' ' 7' ' ' ILE . 4.5 ttpt -66.46 -52.56 44.92 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -49.17 -24.47 4.82 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.22 -45.86 21.89 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.83 -0.806 . . . . 0.0 109.415 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.951 HD12 ' HA ' ' A' ' 4' ' ' LYS . 5.1 mt -57.85 -23.23 20.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.789 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.4 tt -58.32 -37.69 64.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.361 0.6 . . . . 0.0 109.744 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.83 -39.52 24.3 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.131 -1.588 . . . . 0.0 109.131 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.42 HD12 ' HA ' ' A' ' 10' ' ' LEU . 49.0 tp -47.85 -46.92 31.64 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.364 -1.08 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 90.9 mtp . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.496 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -169.67 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.215 -1.167 . . . . 0.0 109.41 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.474 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 55.1 m-20 -126.09 41.52 3.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.36 -0.837 . . . . 0.0 109.3 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.4 tttm -69.25 -51.6 35.91 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.514 -0.741 . . . . 0.0 109.255 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.78 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.14 -23.81 6.12 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 179.485 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.45 -45.48 54.03 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.563 -0.963 . . . . 0.0 109.741 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 11' ' ' MET . 27.3 mm -59.29 -23.26 24.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 CA-C-O 121.903 0.859 . . . . 0.0 108.828 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.836 HD13 ' O ' ' A' ' 8' ' ' ILE . 0.2 OUTLIER -57.64 -31.81 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.476 0.655 . . . . 0.0 109.93 -179.171 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.06 -38.42 6.82 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tp -99.89 72.28 1.7 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.448 -1.03 . . . . 0.0 109.619 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.591 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 t -171.62 58.95 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -1.126 . . . . 0.0 109.354 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.511 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.1 t30 -170.89 49.18 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.198 -0.939 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -61.93 -45.92 91.6 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.146 -0.971 . . . . 0.0 109.103 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.879 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.52 -23.32 6.29 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.511 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.77 -48.76 14.22 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.759 -0.848 . . . . 0.0 109.715 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 46.7 mm -55.11 -23.79 13.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 C-N-CA 119.591 -0.844 . . . . 0.0 108.737 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.879 HG22 ' O ' ' A' ' 5' ' ' GLY . 2.8 tt -64.72 -37.82 81.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.475 -178.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -79.06 -49.67 6.24 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -43.34 -52.91 5.59 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.359 -1.083 . . . . 0.0 109.403 179.917 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 6.9 mmt . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.394 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.511 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 3.6 t 75.49 80.65 0.1 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.278 -1.131 . . . . 0.0 109.4 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.589 ' OD1' ' HB2' ' A' ' 6' ' ' ALA . 2.6 t-20 78.47 43.45 0.08 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.442 -0.786 . . . . 0.0 109.566 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.2 tttt -75.99 -50.97 13.39 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.334 -0.854 . . . . 0.0 109.002 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -53.61 -22.38 17.1 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.589 ' HB2' ' OD1' ' A' ' 3' ' ' ASN . . . -73.9 -42.67 60.34 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.83 -0.806 . . . . 0.0 109.245 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 64.7 mt -58.69 -23.7 23.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.6 mm -64.57 -34.06 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.672 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.11 -47.29 74.2 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.576 -1.809 . . . . 0.0 108.576 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 22.7 tp -60.16 -38.69 83.92 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.669 -0.901 . . . . 0.0 109.54 179.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.435 ' HG3' ' O ' ' A' ' 11' ' ' MET . 9.6 tpt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.564 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.425 ' HB3' ' O ' ' A' ' 1' ' ' GLY . 22.7 t 62.94 127.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.228 -1.16 . . . . 0.0 109.456 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.4 m-20 -172.36 54.04 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.72 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.79 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.4 tttt -62.51 -44.84 95.38 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.083 -1.011 . . . . 0.0 109.13 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -51.06 -22.6 6.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -85.89 -49.26 8.02 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 121.772 -0.84 . . . . 0.0 109.376 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.79 HD12 ' HA ' ' A' ' 4' ' ' LYS . 41.7 mt -48.63 -27.23 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.877 0.846 . . . . 0.0 108.75 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.55 HG23 ' N ' ' A' ' 9' ' ' GLY . 1.9 tt -90.51 -43.16 14.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-O 121.411 0.624 . . . . 0.0 109.712 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.55 ' N ' HG23 ' A' ' 8' ' ' ILE . . . -57.79 -18.57 32.71 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.8 tp -69.87 -45.25 68.12 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.645 -0.915 . . . . 0.0 110.052 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.485 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 15.6 ptt? . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.068 -0.968 . . . . 0.0 109.59 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 21.4 m -63.61 105.41 0.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -1.163 . . . . 0.0 109.426 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.647 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.8 m-20 69.96 47.54 0.59 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.365 -0.835 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 ttpt -63.34 -50.96 67.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.35 -0.844 . . . . 0.0 108.73 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.917 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -51.48 -23.81 10.08 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 178.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.647 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -76.0 -46.13 31.03 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.873 -0.781 . . . . 0.0 109.242 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 13.7 mm -55.37 -24.25 15.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.917 HG22 ' O ' ' A' ' 5' ' ' GLY . 7.2 tt -67.8 -36.27 75.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.323 -178.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.72 -22.11 37.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.419 ' O ' ' C ' ' A' ' 11' ' ' MET . 48.9 tp -73.32 -34.96 65.97 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.378 -1.071 . . . . 0.0 109.784 -179.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.419 ' C ' ' O ' ' A' ' 10' ' ' LEU . 11.3 ptm . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.413 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' A' ' 1' ' ' GLY . 1.4 t 75.53 141.65 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.291 -1.123 . . . . 0.0 109.424 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.539 ' OD1' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -156.85 51.36 0.49 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 179.909 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.414 ' C ' ' N ' ' A' ' 6' ' ' ALA . 15.8 tttm -64.38 -48.16 76.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.676 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -47.86 -25.52 3.68 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB2' ' OD1' ' A' ' 3' ' ' ASN . . . -82.11 -48.66 11.08 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.829 -0.807 . . . . 0.0 109.514 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 15.3 mm -50.43 -25.68 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 119.508 -0.877 . . . . 0.0 108.727 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.676 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.4 OUTLIER -72.17 -40.56 66.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.821 -0.55 . . . . 0.0 110.449 -179.207 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -72.92 -47.63 24.26 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 9' ' ' GLY . 19.0 tp -40.93 -44.35 2.3 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.463 -1.022 . . . . 0.0 109.486 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 34.1 mtt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.368 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.64 163.42 12.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.324 -1.104 . . . . 0.0 109.41 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 2.0 p-10 -139.32 46.82 1.91 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.446 ' HA ' HD13 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -67.9 -47.09 69.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 0.0 109.533 -179.738 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.463 ' O ' ' HB ' ' A' ' 8' ' ' ILE . . . -45.88 -27.32 2.3 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -67.84 -53.55 25.9 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.847 -0.796 . . . . 0.0 109.419 179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.529 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -50.23 -26.61 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.463 ' HB ' ' O ' ' A' ' 5' ' ' GLY . 36.5 mm -75.38 -40.39 42.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.333 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.12 -23.6 64.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.4 ' O ' ' OXT' ' A' ' 11' ' ' MET . 29.6 tp -65.36 -45.93 82.18 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.698 -0.884 . . . . 0.0 109.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.681 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.414 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.33 139.18 11.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.208 -1.172 . . . . 0.0 109.089 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.541 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -147.11 52.06 1.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.193 -0.942 . . . . 0.0 109.54 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -68.05 -42.76 80.05 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.515 -0.741 . . . . 0.0 109.305 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.43 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.16 -24.94 7.31 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.541 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.2 -45.09 58.36 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 122.017 -0.696 . . . . 0.0 109.637 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 HD12 ' A' ' 10' ' ' LEU . 15.9 mm -63.02 -22.27 30.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-O 122.18 0.991 . . . . 0.0 108.368 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.43 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.0 OUTLIER -66.0 -11.07 12.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-O 121.455 0.645 . . . . 0.0 110.095 -178.826 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -114.1 -36.43 1.36 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.714 HD12 HD13 ' A' ' 7' ' ' ILE . 31.5 mt -59.48 -35.52 74.26 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.511 -0.994 . . . . 0.0 108.517 179.322 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.421 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.578 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 22.6 m -84.65 174.2 10.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.567 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.705 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 2.3 m120 72.76 54.84 0.14 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.333 -0.854 . . . . 0.0 109.539 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.48 -48.95 79.52 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.25 -0.906 . . . . 0.0 108.918 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.72 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.53 -24.23 16.74 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.095 -2.002 . . . . 0.0 108.095 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.705 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.32 -44.11 59.6 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 7' ' ' ILE . 46.4 mt -54.82 -24.11 13.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.72 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.6 tt -58.15 -41.14 80.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 120.134 -0.626 . . . . 0.0 109.867 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' A' ' 8' ' ' ILE . . . -74.21 -44.1 29.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 40.6 tp -43.91 -37.21 2.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.435 -1.038 . . . . 0.0 109.317 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 11.6 mtm . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.543 179.941 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -118.71 165.97 13.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.241 -1.153 . . . . 0.0 109.639 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 12.0 p-10 -163.83 49.85 0.14 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.308 -0.87 . . . . 0.0 109.308 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 5' ' ' GLY . 10.3 ttmt -68.0 -49.95 58.48 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.338 -0.851 . . . . 0.0 109.522 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 4' ' ' LYS . . . -46.04 -28.03 2.76 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -66.97 -54.25 23.76 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.865 -0.785 . . . . 0.0 109.076 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 6' ' ' ALA . 42.3 mm -47.53 -26.92 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.486 ' O ' ' HG2' ' A' ' 11' ' ' MET . 11.4 mm -82.13 -39.04 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.021 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.14 -23.1 71.23 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.0 -50.37 72.31 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.587 -0.949 . . . . 0.0 109.545 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.486 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 3.0 ptt? . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.496 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -132.7 100.75 5.04 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.209 -1.171 . . . . 0.0 109.637 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.503 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 11.3 m120 -129.04 41.66 3.44 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.426 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' C ' ' N ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -68.9 -50.86 45.89 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.358 -0.839 . . . . 0.0 109.04 179.791 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.837 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -47.48 -25.67 3.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.322 -1.911 . . . . 0.0 108.322 179.263 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -75.04 -48.21 25.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.793 -0.827 . . . . 0.0 109.292 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 21.2 mm -53.6 -24.55 9.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.836 0.826 . . . . 0.0 108.809 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.837 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.1 OUTLIER -68.96 -39.29 79.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 120.281 -0.567 . . . . 0.0 110.28 -178.944 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.432 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -75.23 -57.48 4.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.399 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.432 ' C ' ' O ' ' A' ' 9' ' ' GLY . 14.7 tp -44.64 -39.4 5.01 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.428 -1.042 . . . . 0.0 108.744 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 2.1 ttm . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.785 179.578 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.47 -170.77 1.91 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.289 -1.124 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.504 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.7 m120 -134.13 44.83 2.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.455 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 44.1 tttt -62.84 -44.19 96.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.394 -0.816 . . . . 0.0 109.069 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.733 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.51 -22.11 10.4 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 179.495 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -75.94 -49.87 16.57 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.598 -0.943 . . . . 0.0 109.09 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 11.4 mt -51.34 -25.55 4.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.554 -0.858 . . . . 0.0 108.719 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.733 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.3 OUTLIER -66.9 -41.63 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 119.792 -0.763 . . . . 0.0 109.971 -179.063 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -68.22 -41.95 84.79 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 9' ' ' GLY . 6.0 tp -41.65 -38.36 1.38 Allowed 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.507 -0.996 . . . . 0.0 109.241 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.666 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.424 ' C ' ' OD1' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -175.84 156.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.287 -1.126 . . . . 0.0 109.135 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.556 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -134.13 45.02 2.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.126 -0.984 . . . . 0.0 109.467 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 tttt -64.99 -43.0 94.0 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.36 -0.838 . . . . 0.0 109.172 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.812 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.22 -27.64 11.57 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 179.127 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.556 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -68.53 -45.99 70.73 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.866 -0.785 . . . . 0.0 108.975 179.233 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 47.5 mm -51.11 -25.09 3.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.812 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.3 OUTLIER -67.68 -41.0 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.669 -0.644 . . . . 0.0 110.269 -179.275 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -78.73 -64.59 1.94 Allowed Glycine 0 N--CA 1.488 2.1 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 179.569 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.472 ' O ' ' C ' ' A' ' 11' ' ' MET . 3.1 tp -45.68 -59.25 2.87 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.514 -0.992 . . . . 0.0 108.374 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.472 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.056 179.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 5.7 m -118.45 72.9 0.89 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.148 -1.207 . . . . 0.0 109.167 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.571 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.1 m-20 167.07 57.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.11 -0.994 . . . . 0.0 109.752 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.4 ttmt -61.63 -49.88 74.8 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.094 -1.004 . . . . 0.0 109.136 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.788 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.62 -24.19 7.43 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 108.585 -1.806 . . . . 0.0 108.585 179.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.571 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.05 -41.68 34.73 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.719 -0.871 . . . . 0.0 109.468 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.522 ' O ' ' CB ' ' A' ' 11' ' ' MET . 13.0 mm -60.46 -21.16 22.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.763 0.792 . . . . 0.0 109.052 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.788 HG22 ' O ' ' A' ' 5' ' ' GLY . 1.1 tt -76.68 -22.89 15.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.824 -0.548 . . . . 0.0 111.206 -178.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.48 -41.92 3.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.3 mt -63.99 -42.67 97.12 Favored 'General case' 0 C--N 1.296 -1.742 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.522 ' CB ' ' O ' ' A' ' 7' ' ' ILE . 1.2 tpt . . . . . 0 C--N 1.302 -1.5 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.334 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.9 t -144.06 140.6 29.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -1.156 . . . . 0.0 109.42 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.6 OUTLIER -143.81 44.91 1.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.258 -0.901 . . . . 0.0 109.389 179.806 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HA ' HD13 ' A' ' 7' ' ' ILE . 12.0 ttpt -62.91 -43.43 98.8 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.476 -0.765 . . . . 0.0 109.228 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.839 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.29 -20.89 7.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.7 -49.5 13.0 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.649 -0.912 . . . . 0.0 109.672 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.63 HD12 ' H ' ' A' ' 7' ' ' ILE . 3.1 mp -58.92 -23.27 23.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.839 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -58.65 -33.71 49.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.294 0.569 . . . . 0.0 110.144 -178.826 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.87 -34.37 89.64 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.2 tp -54.07 -50.78 65.99 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.561 -0.964 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 18.0 mtm . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.053 -0.975 . . . . 0.0 109.477 179.853 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 17.6 m -119.55 154.3 34.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.299 -1.118 . . . . 0.0 109.63 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.696 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 m120 73.33 55.92 0.11 Allowed 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.299 -0.876 . . . . 0.0 108.935 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.745 ' HA ' HD12 ' A' ' 7' ' ' ILE . 2.0 ttpm? -60.98 -50.22 74.25 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.258 -0.901 . . . . 0.0 108.625 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.755 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -48.97 -25.89 5.49 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -77.53 -45.72 24.55 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.976 -0.72 . . . . 0.0 109.569 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.745 HD12 ' HA ' ' A' ' 4' ' ' LYS . 41.9 mt -59.57 -20.85 19.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 CA-C-O 121.962 0.887 . . . . 0.0 108.884 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.755 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.5 tt -58.73 -29.04 38.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.284 0.564 . . . . 0.0 110.265 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.21 -48.39 0.77 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 6' ' ' ALA . 61.4 mt -48.16 -41.02 25.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.216 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.479 ' O ' ' O ' ' A' ' 10' ' ' LEU . 3.9 ptm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.622 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -165.76 -174.22 2.99 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -1.152 . . . . 0.0 109.185 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.535 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.1 t30 -119.26 39.25 3.62 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.141 -0.975 . . . . 0.0 108.943 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.31 -44.6 96.12 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.57 -23.56 6.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.284 -1.926 . . . . 0.0 108.284 179.045 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.535 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -82.76 -47.28 12.13 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.789 -0.83 . . . . 0.0 109.521 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 80.7 mt -55.15 -24.25 14.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 5' ' ' GLY . 8.4 tt -68.0 -36.05 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.917 -0.489 . . . . 0.0 110.595 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -67.21 -46.15 74.36 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 60.0 tp -42.83 -43.2 3.92 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.577 -0.955 . . . . 0.0 109.555 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.546 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.17 126.48 27.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.251 -1.146 . . . . 0.0 109.446 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.577 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.4 OUTLIER 175.34 51.26 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.913 . . . . 0.0 109.603 -179.869 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.946 ' HA ' HD12 ' A' ' 7' ' ' ILE . 16.4 tttt -62.21 -46.56 88.33 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.266 -0.896 . . . . 0.0 109.228 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.758 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -48.78 -24.69 4.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.281 -1.928 . . . . 0.0 108.281 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.26 -52.66 8.32 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.883 -0.775 . . . . 0.0 110.122 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.946 HD12 ' HA ' ' A' ' 4' ' ' LYS . 4.2 mt -52.93 -24.46 7.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 C-N-CA 119.339 -0.944 . . . . 0.0 108.562 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.758 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.4 OUTLIER -71.86 -39.1 67.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.196 0.522 . . . . 0.0 110.168 -179.301 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.43 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -76.63 -60.51 2.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' O ' ' A' ' 9' ' ' GLY . 25.9 tp -43.3 -52.13 5.93 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.104 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 29.8 tpp . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.051 -0.976 . . . . 0.0 109.3 179.791 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 p -67.12 125.05 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.307 -1.113 . . . . 0.0 109.438 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.436 ' HB3' ' HB3' ' A' ' 6' ' ' ALA . 2.5 m120 -167.52 53.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.197 -0.94 . . . . 0.0 109.346 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.9 tttm -67.83 -42.52 81.33 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.101 -0.999 . . . . 0.0 109.555 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -57.53 -16.96 24.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.417 -1.873 . . . . 0.0 108.417 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.436 ' HB3' ' HB3' ' A' ' 3' ' ' ASN . . . -92.11 -42.41 9.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.671 -0.9 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.446 ' HA ' HD13 ' A' ' 7' ' ' ILE . 20.5 mm -52.92 -25.66 9.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.793 0.806 . . . . 0.0 109.104 -179.371 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.599 HG22 ' O ' ' A' ' 5' ' ' GLY . 1.1 tt -81.51 -42.79 19.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.82 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 8' ' ' ILE . . . -69.02 -18.74 73.09 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.3 tp -69.48 -45.15 69.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.472 -1.016 . . . . 0.0 109.192 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' MET . . . . . 0.441 ' SD ' ' HA ' ' A' ' 8' ' ' ILE . 1.5 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.411 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.459 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 12.6 p -168.58 47.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.303 -1.116 . . . . 0.0 109.319 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.605 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 34.8 m120 64.61 45.71 3.44 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.434 -0.791 . . . . 0.0 108.933 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.951 ' HA ' HD12 ' A' ' 7' ' ' ILE . 4.5 ttpt -66.46 -52.56 44.92 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.789 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -49.17 -24.47 4.82 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.22 -45.86 21.89 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.83 -0.806 . . . . 0.0 109.415 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.951 HD12 ' HA ' ' A' ' 4' ' ' LYS . 5.1 mt -57.85 -23.23 20.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.789 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.4 tt -58.32 -37.69 64.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.361 0.6 . . . . 0.0 109.744 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.83 -39.52 24.3 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.131 -1.588 . . . . 0.0 109.131 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.42 HD12 ' HA ' ' A' ' 10' ' ' LEU . 49.0 tp -47.85 -46.92 31.64 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.364 -1.08 . . . . 0.0 109.496 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 90.9 mtp . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.496 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -169.67 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.215 -1.167 . . . . 0.0 109.41 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.474 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 55.1 m-20 -126.09 41.52 3.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.36 -0.837 . . . . 0.0 109.3 179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 12.4 tttm -69.25 -51.6 35.91 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.514 -0.741 . . . . 0.0 109.255 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.78 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.14 -23.81 6.12 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 179.485 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.45 -45.48 54.03 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.563 -0.963 . . . . 0.0 109.741 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 11' ' ' MET . 27.3 mm -59.29 -23.26 24.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 CA-C-O 121.903 0.859 . . . . 0.0 108.828 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.836 ' O ' HD13 ' A' ' 8' ' ' ILE . 0.2 OUTLIER -57.64 -31.81 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 CA-C-O 121.476 0.655 . . . . 0.0 109.93 -179.171 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.06 -38.42 6.82 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 108.706 -1.758 . . . . 0.0 108.706 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tp -99.89 72.28 1.7 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.448 -1.03 . . . . 0.0 109.619 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' A' ' 7' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.075 -0.964 . . . . 0.0 109.591 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 t -171.62 58.95 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -1.126 . . . . 0.0 109.354 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.511 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.1 t30 -170.89 49.18 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.198 -0.939 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.9 tttp -61.93 -45.92 91.6 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.146 -0.971 . . . . 0.0 109.103 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.879 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.52 -23.32 6.29 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.511 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.77 -48.76 14.22 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.759 -0.848 . . . . 0.0 109.715 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 46.7 mm -55.11 -23.79 13.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 C-N-CA 119.591 -0.844 . . . . 0.0 108.737 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.879 HG22 ' O ' ' A' ' 5' ' ' GLY . 2.8 tt -64.72 -37.82 81.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.475 -178.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -79.06 -49.67 6.24 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -43.34 -52.91 5.59 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.359 -1.083 . . . . 0.0 109.403 179.917 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 6.9 mmt . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.394 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.511 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 3.6 t 75.49 80.65 0.1 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.278 -1.131 . . . . 0.0 109.4 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.589 ' OD1' ' HB2' ' A' ' 6' ' ' ALA . 2.6 t-20 78.47 43.45 0.08 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.442 -0.786 . . . . 0.0 109.566 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.2 tttt -75.99 -50.97 13.39 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.334 -0.854 . . . . 0.0 109.002 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -53.61 -22.38 17.1 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.589 ' HB2' ' OD1' ' A' ' 3' ' ' ASN . . . -73.9 -42.67 60.34 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.83 -0.806 . . . . 0.0 109.245 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 64.7 mt -58.69 -23.7 23.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.6 mm -64.57 -34.06 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.672 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.11 -47.29 74.2 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.576 -1.809 . . . . 0.0 108.576 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 22.7 tp -60.16 -38.69 83.92 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.669 -0.901 . . . . 0.0 109.54 179.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.435 ' O ' ' HG3' ' A' ' 11' ' ' MET . 9.6 tpt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.564 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.425 ' HB3' ' O ' ' A' ' 1' ' ' GLY . 22.7 t 62.94 127.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.228 -1.16 . . . . 0.0 109.456 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.4 m-20 -172.36 54.04 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.72 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.79 ' HA ' HD12 ' A' ' 7' ' ' ILE . 6.4 tttt -62.51 -44.84 95.38 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 121.083 -1.011 . . . . 0.0 109.13 179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.479 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -51.06 -22.6 6.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.409 -1.876 . . . . 0.0 108.409 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -85.89 -49.26 8.02 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 121.772 -0.84 . . . . 0.0 109.376 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.79 HD12 ' HA ' ' A' ' 4' ' ' LYS . 41.7 mt -48.63 -27.23 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.877 0.846 . . . . 0.0 108.75 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.55 HG23 ' N ' ' A' ' 9' ' ' GLY . 1.9 tt -90.51 -43.16 14.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-O 121.411 0.624 . . . . 0.0 109.712 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.55 ' N ' HG23 ' A' ' 8' ' ' ILE . . . -57.79 -18.57 32.71 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.684 -1.766 . . . . 0.0 108.684 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.8 tp -69.87 -45.25 68.12 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.645 -0.915 . . . . 0.0 110.052 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.485 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 15.6 ptt? . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.068 -0.968 . . . . 0.0 109.59 -179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.377 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 21.4 m -63.61 105.41 0.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -1.163 . . . . 0.0 109.426 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.647 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.8 m-20 69.96 47.54 0.59 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.365 -0.835 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 ttpt -63.34 -50.96 67.95 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.35 -0.844 . . . . 0.0 108.73 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.917 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -51.48 -23.81 10.08 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 178.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.647 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -76.0 -46.13 31.03 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.873 -0.781 . . . . 0.0 109.242 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 13.7 mm -55.37 -24.25 15.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.917 HG22 ' O ' ' A' ' 5' ' ' GLY . 7.2 tt -67.8 -36.27 75.26 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.323 -178.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.72 -22.11 37.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.419 ' O ' ' C ' ' A' ' 11' ' ' MET . 48.9 tp -73.32 -34.96 65.97 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.378 -1.071 . . . . 0.0 109.784 -179.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.419 ' C ' ' O ' ' A' ' 10' ' ' LEU . 11.3 ptm . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.413 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 2' ' ' SER . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.509 ' CB ' ' O ' ' A' ' 1' ' ' GLY . 1.4 t 75.53 141.65 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.291 -1.123 . . . . 0.0 109.424 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.539 ' OD1' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -156.85 51.36 0.49 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.174 -0.954 . . . . 0.0 109.504 179.909 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.414 ' C ' ' N ' ' A' ' 6' ' ' ALA . 15.8 tttm -64.38 -48.16 76.52 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.676 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -47.86 -25.52 3.68 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.539 ' HB2' ' OD1' ' A' ' 3' ' ' ASN . . . -82.11 -48.66 11.08 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.829 -0.807 . . . . 0.0 109.514 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 15.3 mm -50.43 -25.68 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 119.508 -0.877 . . . . 0.0 108.727 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.676 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.4 OUTLIER -72.17 -40.56 66.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.821 -0.55 . . . . 0.0 110.449 -179.207 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -72.92 -47.63 24.26 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 9' ' ' GLY . 19.0 tp -40.93 -44.35 2.3 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.463 -1.022 . . . . 0.0 109.486 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 34.1 mtt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.368 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.64 163.42 12.35 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.324 -1.104 . . . . 0.0 109.41 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 2.0 p-10 -139.32 46.82 1.91 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.191 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.446 ' HA ' HD13 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -67.9 -47.09 69.77 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 0.0 109.533 -179.738 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.463 ' O ' ' HB ' ' A' ' 8' ' ' ILE . . . -45.88 -27.32 2.3 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -67.84 -53.55 25.9 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.847 -0.796 . . . . 0.0 109.419 179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.529 ' H ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -50.23 -26.61 3.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.463 ' HB ' ' O ' ' A' ' 5' ' ' GLY . 36.5 mm -75.38 -40.39 42.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.333 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.12 -23.6 64.18 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.722 -1.751 . . . . 0.0 108.722 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.4 ' O ' ' OXT' ' A' ' 11' ' ' MET . 29.6 tp -65.36 -45.93 82.18 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.698 -0.884 . . . . 0.0 109.878 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.681 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.414 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -49.33 139.18 11.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.208 -1.172 . . . . 0.0 109.089 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.541 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -147.11 52.06 1.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.193 -0.942 . . . . 0.0 109.54 -179.688 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -68.05 -42.76 80.05 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.515 -0.741 . . . . 0.0 109.305 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.43 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.16 -24.94 7.31 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.541 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.2 -45.09 58.36 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 122.017 -0.696 . . . . 0.0 109.637 179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 HD12 ' A' ' 10' ' ' LEU . 15.9 mm -63.02 -22.27 30.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-O 122.18 0.991 . . . . 0.0 108.368 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.43 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.0 OUTLIER -66.0 -11.07 12.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-O 121.455 0.645 . . . . 0.0 110.095 -178.826 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -114.1 -36.43 1.36 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.714 HD12 HD13 ' A' ' 7' ' ' ILE . 31.5 mt -59.48 -35.52 74.26 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.511 -0.994 . . . . 0.0 108.517 179.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.421 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 117.942 -1.028 . . . . 0.0 109.578 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 22.6 m -84.65 174.2 10.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.567 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.705 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 m-80 72.76 54.84 0.14 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.333 -0.854 . . . . 0.0 109.539 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.48 -48.95 79.52 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.25 -0.906 . . . . 0.0 108.918 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.72 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.53 -24.23 16.74 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.095 -2.002 . . . . 0.0 108.095 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.705 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -73.32 -44.11 59.6 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 7' ' ' ILE . 46.4 mt -54.82 -24.11 13.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.72 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.6 tt -58.15 -41.14 80.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 120.134 -0.626 . . . . 0.0 109.867 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' A' ' 8' ' ' ILE . . . -74.21 -44.1 29.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 40.6 tp -43.91 -37.21 2.74 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.435 -1.038 . . . . 0.0 109.317 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 11.6 mtm . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.543 179.941 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 m -118.71 165.97 13.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.241 -1.153 . . . . 0.0 109.639 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.55 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 12.0 p-10 -163.83 49.85 0.14 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.308 -0.87 . . . . 0.0 109.308 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 5' ' ' GLY . 10.3 ttmt -68.0 -49.95 58.48 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.338 -0.851 . . . . 0.0 109.522 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 4' ' ' LYS . . . -46.04 -28.03 2.76 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -66.97 -54.25 23.76 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.865 -0.785 . . . . 0.0 109.076 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 6' ' ' ALA . 42.3 mm -47.53 -26.92 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.486 ' O ' ' HG2' ' A' ' 11' ' ' MET . 11.4 mm -82.13 -39.04 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.021 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.14 -23.1 71.23 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.0 -50.37 72.31 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.587 -0.949 . . . . 0.0 109.545 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.486 ' HG2' ' O ' ' A' ' 8' ' ' ILE . 3.0 ptt? . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.076 -0.964 . . . . 0.0 109.496 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.9 t -132.7 100.75 5.04 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.209 -1.171 . . . . 0.0 109.637 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.503 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 11.3 m120 -129.04 41.66 3.44 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.426 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' C ' ' N ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -68.9 -50.86 45.89 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.358 -0.839 . . . . 0.0 109.04 179.791 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.837 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -47.48 -25.67 3.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.322 -1.911 . . . . 0.0 108.322 179.263 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -75.04 -48.21 25.12 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.793 -0.827 . . . . 0.0 109.292 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 21.2 mm -53.6 -24.55 9.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 CA-C-O 121.836 0.826 . . . . 0.0 108.809 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.837 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.1 OUTLIER -68.96 -39.29 79.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 C-N-CA 120.281 -0.567 . . . . 0.0 110.28 -178.944 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.432 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -75.23 -57.48 4.31 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 179.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.432 ' C ' ' O ' ' A' ' 9' ' ' GLY . 14.7 tp -44.64 -39.4 5.01 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.428 -1.042 . . . . 0.0 108.744 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 2.1 ttm . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.785 179.578 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.47 -170.77 1.91 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.289 -1.124 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.504 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.7 m120 -134.13 44.83 2.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.218 -0.926 . . . . 0.0 109.455 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 44.1 tttt -62.84 -44.19 96.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.394 -0.816 . . . . 0.0 109.069 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.733 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.51 -22.11 10.4 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 179.495 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.504 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -75.94 -49.87 16.57 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.598 -0.943 . . . . 0.0 109.09 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 11.4 mt -51.34 -25.55 4.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 119.554 -0.858 . . . . 0.0 108.719 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.733 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.3 OUTLIER -66.9 -41.63 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 119.792 -0.763 . . . . 0.0 109.971 -179.063 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.444 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -68.22 -41.95 84.79 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 9' ' ' GLY . 6.0 tp -41.65 -38.36 1.38 Allowed 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.507 -0.996 . . . . 0.0 109.241 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.666 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.424 ' C ' ' OD1' ' A' ' 3' ' ' ASN . 0.6 OUTLIER -175.84 156.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.287 -1.126 . . . . 0.0 109.135 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.556 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -134.13 45.02 2.66 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.126 -0.984 . . . . 0.0 109.467 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 tttt -64.99 -43.0 94.0 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.36 -0.838 . . . . 0.0 109.172 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.812 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.22 -27.64 11.57 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 179.127 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.556 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -68.53 -45.99 70.73 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.866 -0.785 . . . . 0.0 108.975 179.233 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 47.5 mm -51.11 -25.09 3.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.812 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.3 OUTLIER -67.68 -41.0 85.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.669 -0.644 . . . . 0.0 110.269 -179.275 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -78.73 -64.59 1.94 Allowed Glycine 0 N--CA 1.488 2.1 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 179.569 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.472 ' O ' ' C ' ' A' ' 11' ' ' MET . 3.1 tp -45.68 -59.25 2.87 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.514 -0.992 . . . . 0.0 108.374 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.472 ' C ' ' O ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.056 179.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 5.7 m -118.45 72.9 0.89 Allowed 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.148 -1.207 . . . . 0.0 109.167 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.571 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 1.1 m-20 167.07 57.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.11 -0.994 . . . . 0.0 109.752 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.4 ttmt -61.63 -49.88 74.8 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.094 -1.004 . . . . 0.0 109.136 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.788 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.62 -24.19 7.43 Favored Glycine 0 N--CA 1.487 2.098 0 N-CA-C 108.585 -1.806 . . . . 0.0 108.585 179.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.571 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.05 -41.68 34.73 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.719 -0.871 . . . . 0.0 109.468 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.522 ' O ' ' CB ' ' A' ' 11' ' ' MET . 13.0 mm -60.46 -21.16 22.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.763 0.792 . . . . 0.0 109.052 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.788 HG22 ' O ' ' A' ' 5' ' ' GLY . 1.1 tt -76.68 -22.89 15.12 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.824 -0.548 . . . . 0.0 111.206 -178.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -97.48 -41.92 3.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.3 mt -63.99 -42.67 97.12 Favored 'General case' 0 C--N 1.296 -1.742 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.522 ' CB ' ' O ' ' A' ' 7' ' ' ILE . 1.2 tpt . . . . . 0 C--N 1.302 -1.5 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.334 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.355 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.9 t -144.06 140.6 29.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.234 -1.156 . . . . 0.0 109.42 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.496 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.6 OUTLIER -143.81 44.91 1.48 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.258 -0.901 . . . . 0.0 109.389 179.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HA ' HD13 ' A' ' 7' ' ' ILE . 12.0 ttpt -62.91 -43.43 98.8 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.476 -0.765 . . . . 0.0 109.228 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.839 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -52.29 -20.89 7.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.7 -49.5 13.0 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.649 -0.912 . . . . 0.0 109.672 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.63 ' H ' HD12 ' A' ' 7' ' ' ILE . 3.1 mp -58.92 -23.27 23.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.839 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.8 OUTLIER -58.65 -33.71 49.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 CA-C-O 121.294 0.569 . . . . 0.0 110.144 -178.826 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.87 -34.37 89.64 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.2 tp -54.07 -50.78 65.99 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.561 -0.964 . . . . 0.0 109.383 179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 18.0 mtm . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.053 -0.975 . . . . 0.0 109.477 179.853 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 3' ' ' ASN . 17.6 m -119.55 154.3 34.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.299 -1.118 . . . . 0.0 109.63 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.696 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 m120 73.33 55.92 0.11 Allowed 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.299 -0.876 . . . . 0.0 108.935 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.745 ' HA ' HD12 ' A' ' 7' ' ' ILE . 2.0 ttpm? -60.98 -50.22 74.25 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.258 -0.901 . . . . 0.0 108.625 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.755 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -48.97 -25.89 5.49 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -77.53 -45.72 24.55 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.976 -0.72 . . . . 0.0 109.569 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.745 HD12 ' HA ' ' A' ' 4' ' ' LYS . 41.9 mt -59.57 -20.85 19.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 CA-C-O 121.962 0.887 . . . . 0.0 108.884 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.755 HG22 ' O ' ' A' ' 5' ' ' GLY . 6.5 tt -58.73 -29.04 38.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 CA-C-O 121.284 0.564 . . . . 0.0 110.265 -179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.21 -48.39 0.77 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 108.732 -1.747 . . . . 0.0 108.732 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 6' ' ' ALA . 61.4 mt -48.16 -41.02 25.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.216 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.479 ' O ' ' O ' ' A' ' 10' ' ' LEU . 3.9 ptm . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.622 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -165.76 -174.22 2.99 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.242 -1.152 . . . . 0.0 109.185 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.535 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.2 OUTLIER -119.26 39.25 3.62 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.141 -0.975 . . . . 0.0 108.943 179.589 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.31 -44.6 96.12 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.93 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -50.57 -23.56 6.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.284 -1.926 . . . . 0.0 108.284 179.045 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.535 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -82.76 -47.28 12.13 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.789 -0.83 . . . . 0.0 109.521 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 80.7 mt -55.15 -24.25 14.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 5' ' ' GLY . 8.4 tt -68.0 -36.05 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.917 -0.489 . . . . 0.0 110.595 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -67.21 -46.15 74.36 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 9' ' ' GLY . 60.0 tp -42.83 -43.2 3.92 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.577 -0.955 . . . . 0.0 109.555 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.546 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.17 126.48 27.87 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.251 -1.146 . . . . 0.0 109.446 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.577 ' O ' ' HB3' ' A' ' 6' ' ' ALA . 0.4 OUTLIER 175.34 51.26 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.913 . . . . 0.0 109.603 -179.869 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.946 ' HA ' HD12 ' A' ' 7' ' ' ILE . 16.4 tttt -62.21 -46.56 88.33 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.266 -0.896 . . . . 0.0 109.228 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.758 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -48.78 -24.69 4.38 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.281 -1.928 . . . . 0.0 108.281 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 3' ' ' ASN . . . -78.26 -52.66 8.32 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.883 -0.775 . . . . 0.0 110.122 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.946 HD12 ' HA ' ' A' ' 4' ' ' LYS . 4.2 mt -52.93 -24.46 7.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 C-N-CA 119.339 -0.944 . . . . 0.0 108.562 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.758 HG22 ' O ' ' A' ' 5' ' ' GLY . 0.4 OUTLIER -71.86 -39.1 67.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.196 0.522 . . . . 0.0 110.168 -179.301 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.43 ' O ' ' C ' ' A' ' 10' ' ' LEU . . . -76.63 -60.51 2.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.099 -1.6 . . . . 0.0 109.099 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' O ' ' A' ' 9' ' ' GLY . 25.9 tp -43.3 -52.13 5.93 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.104 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . . . . . . . . . 29.8 tpp . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 118.051 -0.976 . . . . 0.0 109.3 179.791 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 p -67.12 125.05 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.307 -1.113 . . . . 0.0 109.438 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.436 ' HB3' ' HB3' ' A' ' 6' ' ' ALA . 2.5 m120 -167.52 53.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.197 -0.94 . . . . 0.0 109.346 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.9 tttm -67.83 -42.52 81.33 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.101 -0.999 . . . . 0.0 109.555 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 8' ' ' ILE . . . -57.53 -16.96 24.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.417 -1.873 . . . . 0.0 108.417 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.436 ' HB3' ' HB3' ' A' ' 3' ' ' ASN . . . -92.11 -42.41 9.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.671 -0.9 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.446 HD13 ' HA ' ' A' ' 7' ' ' ILE . 20.5 mm -52.92 -25.66 9.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.793 0.806 . . . . 0.0 109.104 -179.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.599 HG22 ' O ' ' A' ' 5' ' ' GLY . 1.1 tt -81.51 -42.79 19.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.82 -179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.567 ' N ' HG23 ' A' ' 8' ' ' ILE . . . -69.02 -18.74 73.09 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.3 tp -69.48 -45.15 69.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.472 -1.016 . . . . 0.0 109.192 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' MET . . . . . 0.441 ' SD ' ' HA ' ' A' ' 8' ' ' ILE . 1.5 mtp . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.904 -1.046 . . . . 0.0 109.411 179.94 . . . . . . . . 1 1 . 1 stop_ save_